BamSEC and AlphaSense Join Forces
Learn More

BridgeBio Pharma Inc. – Material Contracts

NASDAQ: BBIO    
Share price (4/6/26): $72.28    
Market cap (4/6/26): $14.0 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.25
from 10-K 3 pages BridgeBio Pharma, Inc. Amended and Restated Director Compensation Policy Effective Date: December 11, 2025
12/34/56
EX-10.17
from 10-K 2 pages Amendment No. 4 to Consulting Agreement
12/34/56
EX-10.16
from 10-K 2 pages Amendment No. 3 to Consulting Agreement
12/34/56
EX-10.2
from 10-Q 117 pages Certain Information Identified by “[***]” Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. First Amendment to Funding Agreement
12/34/56
EX-10.1
from 10-Q 72 pages Certain Information Identified by “[***]” Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. Royalty Interest Purchase and Sale Agreement by and Among Eidos Therapeutics, Inc., as the Company and BridgeBio Pharma, Inc., as the Parent, on the One Hand and Acoramidis Royalty Spv, LP and Lsi Financing Fund, LP, as the Purchasers and Acoramidis Royalty Spv, LP, as the Purchaser Representative, on the Other Hand Dated June 27, 2025
12/34/56
EX-10.1
from 8-K 51 pages BridgeBio Pharma, Inc. Second Amended and Restated 2021 Stock Option and Incentive Plan
12/34/56
EX-10.1
from 10-Q 7 pages [***] Certain Information in This Document Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Consulting Agreement
12/34/56
EX-10.42
from 10-K 5 pages Certain Information Identified by “[***]” Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential
12/34/56
EX-10.2
from 8-K 91 pages Amended and Restated Limited Liability Company Agreement of Bridgebiox Pharma, LLC, a Delaware Limited Liability Company Dated as of August 16, 2024
12/34/56
EX-10.1
from 8-K 75 pages Transaction Agreement Dated as of August 16, 2024 by and Among
12/34/56
EX-10.2
from 10-Q 70 pages 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan
12/34/56
EX-10.1
from 10-Q 163 pages Certain Information Identified by “[***]” Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. Second Amendment to Financing Agreement
12/34/56
EX-10.1
from 8-K 12 pages 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan
12/34/56
EX-10.7
from 10-Q 4 pages Amendment No. 3 to Consulting Agreement
12/34/56
EX-10.6
from 10-Q 4 pages Amendment № 3 to the Exclusive (Equity) Agreement Effective the 10th Day of April 2016 Between the Board of Trustees of the Leland Stanford Junior University and Eidos Therapeutics, Inc
12/34/56
EX-10.5
from 10-Q 83 pages Certain Information Identified by “[***]” Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. Exclusive License Agreement by and Among Eidos Therapeutics, Inc., BridgeBio International Gmbh, BridgeBio Europe B.V., and Bayer Consumer Care AG Entered Into as of March 1st, 2024
12/34/56
EX-10.4
from 10-Q 105 pages Certain Information Identified by “[***]” Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. Funding Agreement
12/34/56
EX-10.3
from 10-Q 17 pages Certain Information Identified by “[***]” Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. First Amendment to Financing Agreement
12/34/56
EX-10.2
from 10-Q 156 pages Certain Information Identified by “[***]” Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. Financing Agreement Dated as of January 17, 2024 Among BridgeBio Pharma, Inc., as the Borrower, Certain Subsidiaries of the Borrower From Time to Time Party Hereto, as Guarantors, Various Lenders From Time to Time Party Hereto, and Blue Owl Capital Corporation as Administrative Agent
12/34/56
EX-10.39
from 10-K 4 pages Certain Information Identified by “[***]” Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential
12/34/56